论文部分内容阅读
[目的]探讨乌司他丁联合连续性肾脏替代治疗(CRRT)对Ⅰ型急性心肾综合征(ACRS)的临床疗效.[方法]120例ACRS患者随机分为两组,各60例.对照组给予CRRT治疗,观察组在对照组基础上给予乌司他丁治疗,连用3d.治疗14d后比较两组疗效及心、肾功能变化.[结果]观察组存活率为83.33％(50/60)略高于对照组的71.66％(43/60),治疗后肾功能恢复正常率、心功能Ⅱ～Ⅲ级率分别为45.0％(27/60)、25.0％(15/60),略高于对照组的31.67％(19/60)、15.0％(9/60),但差异均无显著性(P＞0.05).观察组治疗后左心室射血分数(LVEF)、内生肌酐清除率(Ccr)、肾小球滤过率(GFR)高于对照组,血浆氨基末端B型利钠肽前体(NT-proB-NP)、肌酐(SCr)低于对照组,且差异有显著性(P＜0.05).[结论]乌司他丁联合CRRT治疗ACRS可保护患者心、肾功能,但对近期预后改善不明显.“,”[Objective] To investigate the clinical curative effect of ulinastatin combined with continuous renal re-placement therapy(CRRT)in the treatment of type I acute cardiorenal syndrome(ACRS).[Methods]A total of 120 pa-tients with ACRS were divided into two groups by the random method,with 60 cases in each group.Patients in the con-trol group were given CRRT while patients in the observation group were treated with ulinastatin for 3 consecutive days in addition to CRRT.The renal and cardiac function were evaluated between the two groups after 14 days of treatment.The levels of plasma creatinine(Scr)and NT-proBNP were detected.The Ccr and GFR were calculated.The LVEF was diag-nosed.[Results] The survival rate of the observation group was 83.33％(50/60),which was slightly higher than that of the control group 71.66％(43/60).The recovery rate of renal function and the rate of grade Ⅱ to Ⅲ of the heart function after treatment in the observation group were 45.0％(27/60)and 25.0％(15/60),respectively,which were slightly higher than those in the control group,which were 31.67％(19/60),and 15.0％(9/60),respectively.However,those differences were not statistically significant(P ＞0.05).After treatment,LVEF(left ventricular ejection fraction),Ccr(endogenous creatinine clearance)and GFR(glomerular filtration rate)were higher in the observation group than those in the control group,while levels of NT-proBNP(plasma N-terminal B-type natriuretic peptide precursor)and Scr(creati-nine)were lower than in the control group,and the difference was statistically significant(P ＜0.05).[Conclusion] The application of ulinastatin combined with CRRT in the treatment of ACRS can protect cardiac and renal function,but the improvement of short-term prognosis is not obvious.